

DPA



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : LaRosa et al.

Art Unit : 1648

Serial No. : 10/766,773

Examiner : Agnieszka Boesen

Filed : January 27, 2004

Title : HUMANIZED ANTI-CCR2 ANTIBODIES AND METHODS OF USE
THEREFOR**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

AMENDMENT & RESPONSE TO RESTRICTION REQUIREMENT

Responsive to the action mailed March 13, 2006, applicants elect the invention of Group IX drawn to the embodiment of treating a CCR2-mediated disorder in a patient.

Applicants note that Group V (directed to methods of treating HIV) and Group X (directed to methods of treating restenosis) are also drawn to specific CCR-2 mediated disorders. Therefore, the claims covering these embodiments have been amended to depend from claims 36, 54 or dependencies of claims 36 or 54. For searching purposes, applicants elect the species of rheumatoid arthritis. Claims 36, 50, 54 and 56-58 read on the elected species. The species election is made without traverse.

Please amend the application as follows:

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

7/18/06

Date of Deposit

Signature

Typed or Printed Name of Person Signing Certificate

A Passacantilli

APASSACANTILLI